Management of bipolar disorder in the intercontinental region: An international, multicenter, non-interventional, cross-sectional study in real-life conditions

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Samalin, Ludovic ^a,b   Vieta, Eduard ^b   Okasha, Tarek Ahmed ^c   Uddin, M M Jalal ^d   Ahmadi Abhari, Seyed Ali ^e   Nacef, Fethi ^f   Mishyiev, Vyacheslav ^g   Aizenberg, Dovi ^h   Ratner, Yaël ⁱ   Melas Melt, Lydie ^j   Sedeki, Idir ^k   Llorca, Pierre Michel ^a  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^b UNIVERSITY OF BARCELONA   (Spain)

^c AIN SHAMS UNIVERSITY   (Egypt)

^d National Institute of Neurosciences and Hospital   (Bangladesh)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f RAZI HOSPITAL   (Tunisia)

^g Kyiv Psycho Neurological Clinic N 2   (Ukraine)

^h TEL AVIV UNIVERSITY   (Israel)

ⁱ TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^j Biostatistician   (France)

^k SANOFI   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; BIPOLAR DISORDER; CLINICAL TRIAL; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE MANAGEMENT; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; TIME TO TREATMENT;

ADULT; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE MANAGEMENT; FEMALE; HUMANS; MALE; MIDDLE AGED; TIME-TO-TREATMENT;

EID: 84968903196     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep25920     Document Type: Article

References (47)

1. World Health Organization. The Global Burden of Disease: 2004 Update. (2008) Available at:http://www.who.int/healthinfo/global-burden-disease/2004-report-update/en/ (Accessed: 28th September 2015).
2. Samalin, L. et al. Residual symptoms and functional performance in a large sample of euthymic bipolar patients in France (the OPTHYMUM study). J. Affect. Disord. 159, 94-102 (2014).
3. Sanchez-Moreno, J. et al. Functioning and disability in bipolar disorder: an extensive review. Psychother. Psychosom. 78, 285-297 (2009).
4. Bauer, M. S., Kirk, G., Gavin, C. & Williford, W. O. Determinants of functional outcome and healthcare costs in bipolar disorder: a high-intensity follow-up study. J. Affect. Disord. 65, 231-241 (2001).
5. Kleinman, L. et al. Costs of bipolar disorder. Pharmaco-economics 21, 601-622 (2001).
6. Bryant-Comstock, L., Stender, M. & Devercelli, G. Health care utilization and costs among privately insured patients with bipolar I disorder. Bipolar Disord. 4, 398-405 (2002).
7. Kessler, R. C. et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry 51, 8-19 (1994).
8. Weissman, M. et al. Cross-national epidemiology of major depression and bipolar disorder. JAMA 276, 293-299 (1996).
9. Waraich, P., Goldner, E. M., Somers, J. M. & Hsu, L. Prevalence and incidence studies of mood disorders: a systematic review of the literature. Can J Psychiatry 49, 124-138 (2004).
10. Angst, J. The emerging epidemiology of hypomania and bipolar II disorder. J. Affect. Disord. 50, 143-151 (1998).
11. Hirschfeld, R. M. Bipolar spectrum disorder: improving its recognition and diagnosis. J. Clin. Psychiatry 62, 5-9 (2001).
12. Merikangas, K. R. & Lamers, F. The 'true' prevalence of bipolar II disorder. Curr. Opin. Psychiatry 25, 19-23 (2012).
13. Vieta, E. & Suppes, T. Bipolar II disorder: arguments for and against a distinct diagnostic entity. Bipolar Disord. 10, 163-178 (2008).
14. Goodwin, G. M.et al.Evidence-based guidelines for treating bipolar bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J. Psycho-pharmacol. [cited 2016 Mar 15] doi:10.1177/0269881116636545. (2016).
15. Grunze, H. et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of bipolar disorder. World J. Biol. Psychiatry 14, 154-219 (2013).
16. National Institute for Health and Clinical Excellence. Bipolar disorder: the assessment and management of bipolar disorder in adults, children and young people in primary and secondary care (2015) Available at: http://www.nice.org.uk/guidance/cg185/resources/guidance-bipolar-disorder-the-assessment-and-management-of-bipolar-disorder-in-adults-children-and-young-people-in-primary-and-secondary-care-pdf. (Accessed: 28th September 2015).
17. Yatham, L. N. et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 15, 1-44 (2013).
18. Malhi, G. S. et al. Clinical practice recommendations for bipolar disorder. Acta Psychiatr. Scand. Suppl. 439, 27-46 (2009).
19. Samalin, L., Guillaume, S., Auclair, C. & Llorca, P. M. Adherence to guidelines by French psychiatrists in their real world of clinical practice. J. Nerv. Ment. Dis. 199, 239-243 (2011).
20. Perlis, R. H. Use of treatment guidelines in clinical decision making in bipolar disorder: a pilot survey of clinicians. Curr. Med. Res. Opin. 23, 467-475 (2007).
21. Haro, J. M. et al. Evidence for three distinct classes of 'typical', 'psychotic' and 'dual' mania: results from the EMBLEM study. Acta Psychiatr. Scand. 113, 112-120 (2006).
22. Henry, C. et al. A French network of bipolar expert centres: a model to close the gap between evidence-based medicine and routine practice. J. Affect. Disord. 131, 358-363 (2011).
23. Sachs, G. S. et al. Rationale, design and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol. Psychiatry 53, 1028-1042 (2003).
24. Ghaemi, S. N. et al. Pharmacological Treatment Patterns at Study Entry for the First 500 STEP-BD Participants. Psychiatr. Serv. 57, 660-665 (2006).
25. Vieta, E. et al. Clinical management and burden of bipolar disorder: results from a multinational longitudinal study (WAVE-bd). Int. J. Neuropsychopharmacol. 16, 1719-1732 (2013).
26. Carlborg, A., Ferntoft, L., Thuresson, M. & Bodegard, J. Population study of disease burden, management, and treatment of bipolar disorder in Sweden: a retrospective observational registry study. Bipolar Disord. 17, 76-85 (2015).
27. Hayes, J. et al. Prescribing trends in bipolar disorder: cohort study in the United Kingdom THIN primary care database 1995-2009. PLos One 6, e28725 (2011).
28. Baldessarini, R., Henk, H., Sklar, A., Chang, J. & Leahy, L. Psychotropic medications for patients with bipolar disorder in the United States: polytherapy and adherence. Psychiatr. Serv. 59, 1175-1183 (2008).
29. Grande, I. et al. Patterns of pharmacological maintenance treatment in a community mental health services bipolar disorder cohort study (SIN-DEPRES). Int. J. Neuro-psychopharmacol. 16, 513-523 (2013).
30. Blanco, C., Laje, G., Olfson, M., Marcus, S. C. & Pincus, H. A. Trends in the treatment of bipolar disorder by outpatient psychiatrists. Am. J. Psychiatry 159, 1005-1010 (2002).
31. Walpoth-Niederwanger, M. et al. Treatment patterns in inpatients with bipolar disorder at a psychiatric university hospital over a 9-year period: focus on mood stabilizers. Int. Clin. Psychopharmacol. 27, 256-266 (2012).
32. Kessing, L. V., Vradi, E. & Andersen, P. K. Nationwide and population-based prescription patterns in bipolar disorder. Bipolar Disord. 18, 174-182 (2016).
33. Karanti, A., Kardell, M., Lundberg, U. & Landén, M. Changes in mood stabilizer prescription patterns in bipolar disorder. J. Affect. Disord. 195, 50-56 (2016).
34. Okasha, T. A. et al. Longer-term treatment of patients with bipolar disorder: a 9-month observational study in Central and Eastern Europe, the Middle East and Africa. Curr. Med. Res. Opin. 25, 1889-1900 (2009).
35. Hall, R. C. W. Global Assessment of Functioning: A Modified Scale. Psychosomatics 36, 267-275 (1995).
36. Hirschfeld, R. M. Differential diagnosis of bipolar disorder and major depressive disorder. J. Affect. Disord. 169, 12-16 (2014).
37. Ghouse, A. A., Sanches, M., Zunta-Soares, G., Swann, A. C. & Soares, J. C. Over diagnosis of bipolar disorder: a critical analysis of the literature. Scientific World Journal 2013, 297087 (2013).
38. Keck, P. E., Kessler, R. C. & Ross, R. Clinical and economic effects of unrecognized or inadequately treated bipolar disorder. J. Psychiatr. Pract. 14, 31-38 (2008).
39. Carvalho, A. F. et al. Screening for bipolar spectrum disorders: A comprehensive meta-analysis of accuracy studies. J. Affect. Disord. 172C, 337-346 (2014).
40. Mitchell, A. J. Clinical utility of screening for clinical depression and bipolar disorder. Curr. Opin. Psychiatry 25, 24-31 (2012).
41. Phillips, M. L. & Kupfer, D. J. Bipolar disorder diagnosis: challenges and future directions. The Lancet 381, 1663-1671 (2013).
42. Pacchiarotti, I. et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am. J. Psychiatry 170, 1249-1262 (2013).
43. Samalin, L. et al. Methodological differences between pharmacological treatment guidelines for bipolar disorder: what to do for the clinicians? Compr. Psychiatry 54, 309-320 (2013).
44. Amsterdam, J. D. et al. Safety and effectiveness of continuation antidepressant versus mood stabilizer monotherapy for relapse-prevention of bipolar II depression: A randomized, double-blind, parallel-group, prospective study. J Affect. Disord. 185, 31-37 (2015).
45. Amsterdam, J. D. & Shults, J. Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study. Am. J. Psychiatry 167, 792-800 (2010).
46. Castellani, A., Girlanda, F. & Barbui, C. Rigor of development of clinical practice guidelines for the pharmacological treatment of bipolar disorder: systematic review. J. Affect. Disord. 174, 45-50 (2015).
47. Nivoli, A. M., Murru, A. & Vieta, E. Lithium: still a cornerstone in the long-term treatment in bipolar disorder? Neuro-psychobiology 62, 27-35 (2010).